Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BLC
MCID: BLD134
MIFTS: 70

Bladder Cancer (BLC)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Cancer

About this section

MalaCards integrated aliases for Bladder Cancer:

Name: Bladder Cancer 58 12 54 26 76 38 56 44 15 39
Bladder Carcinoma 39 12 30 56 6 15 17
Bladder Cancer, Somatic 58 30 13 6
Urinary Bladder Cancer 12 26 76 15
Malignant Neoplasm of Urinary Bladder 74
Urothelial Carcinoma of the Bladder 76
Malignant Tumor of Urinary Bladder 26
Carcinoma of Urinary Bladder 12
Urinary Bladder Neoplasms 45
Cancer of the Bladder 26
Tumor of the Bladder 12
Carcinoma of Bladder 74
Bladder Neoplasm 74
Cancer, Bladder 41
Bladder Tumors 56
Bladder Tumor 17
Blc 76

Characteristics:

OMIM:

58
Inheritance:
somatic mutation


HPO:

33
bladder cancer:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:11054 DOID:4007
OMIM 58 109800
KEGG 38 H00022
ICD9CM 36 188 188.9
MeSH 45 D001749
SNOMED-CT 69 93689003
ICD10 34 C67 C67.9
MedGen 43 C0005684
SNOMED-CT via HPO 70 255109008 263681008
Sources

Summaries for Bladder Cancer

About this section
MedlinePlus : 44 The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States. Symptoms include Blood in your urine A frequent urge to urinate Pain when you urinate Low back pain Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk. Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Bladder Cancer, also known as bladder carcinoma, is related to transitional cell carcinoma and bladder adenocarcinoma. An important gene associated with Bladder Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Bladder cancer and MicroRNAs in cancer. The drugs Valstar and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and lymph node, and related phenotype is transitional cell carcinoma of the bladder.

Disease Ontology : 12 An urinary system cancer that results in malignant growth located in the urinary bladder.

Genetics Home Reference : 26 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).

NIH Rare Diseases : 54 Bladder cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the bladder. Signs and symptoms of the condition may include abdominal pain, blood in the urine, fatigue, painful urination, frequent urination, incontinence, and/or weightloss. Most cases of bladder cancer occur sporadically in people with no family history of the condition. Risk factors for the condition include smoking, exposure to certain chemicals, and having chronic bladder infections. Treatment varies based on the severity of the condition and may include surgery, radiation therapy, chemotherapy, and/or biological therapy.

UniProtKB/Swiss-Prot : 76 Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Wikipedia : 77 Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is... more...

Description from OMIM: 109800
Sources

Related Diseases for Bladder Cancer

About this section

Diseases in the Bladder Cancer family:

Bladder Carcinoma in Situ

Diseases related to Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 445)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 33.0 BRINP1 FGFR3 HRAS
2 bladder adenocarcinoma 32.3 HRAS UCA1
3 prostate cancer 31.4 GAS5 H19 HRAS KRAS MIR10B MIR127
4 bladder urothelial carcinoma 31.3 FGFR3 GAS5 HRAS KRAS RB1 TUG1
5 adenocarcinoma 31.1 FGFR3 H19 HRAS KRAS RB1
6 lung cancer 31.1 BLACAT1 FGFR3 GAS5 GHET1 H19 HRAS
7 renal cell carcinoma, nonpapillary 31.1 GAS5 H19 TSC1 TUG1 UCA1
8 squamous cell carcinoma 31.1 FGFR3 H19 HRAS RB1 TUG1 UCA1
9 breast cancer 30.8 GAS5 H19 HRAS KRAS MIR10B MIR127
10 gallbladder cancer 30.7 H19 KRAS TUG1 UCA1
11 melanoma 30.6 GAS5 H19 MIR127 MIR221 UCA1
12 kidney cancer 30.6 GAS5 H19 MIR21
13 gastric cancer 30.6 BLACAT1 GAS5 GHET1 H19 KRAS MIR143
14 nevus, epidermal 30.5 FGFR3 HRAS KRAS
15 myeloma, multiple 30.5 FGFR3 GAS5 H19 HRAS KRAS TUG1
16 leukemia, chronic lymphocytic 2 30.5 HRAS KRAS MIR143
17 lung cancer susceptibility 3 30.5 BLACAT1 FGFR3 GAS5 H19 HRAS KRAS
18 cervical cancer 30.5 BLACAT1 FGFR3 GAS5 H19 HRAS MIR143
19 colorectal cancer 30.5 BLACAT1 FGFR3 GAS5 GHET1 H19 HRAS
20 cholangiocarcinoma 30.4 H19 KRAS MIR21 TUG1 UCA1
21 intrahepatic cholangiocarcinoma 30.3 KRAS MIR127 TUG1
22 glioblastoma 30.3 GAS5 H19 HRAS MIR10B MIR21 MIR221
23 polymyositis 30.3 MIR127 MIR21
24 ovarian cancer 30.2 GAS5 H19 KRAS MIR10B MIR127 MIR143
25 small cell cancer of the lung 29.9 MIR21 RB1 TUG1
26 superficial urinary bladder cancer 12.3
27 jewett-marshall bladder cancer 12.2
28 bladder cancer, childhood 12.2
29 gall bladder carcinoma in situ 12.1
30 small cell carcinoma of the bladder 12.0
31 chondrodysplasia, blomstrand type 11.8
32 schistosomiasis 11.4
33 urinary bladder small cell neuroendocrine carcinoma 11.3
34 urinary schistosomiasis 11.3
35 urachal cancer 11.1
36 pseudo-torch syndrome 1 11.1
37 congenital intrauterine infection-like syndrome 11.1
38 bladder squamous cell carcinoma 11.1
39 danubian endemic familial nephropathy 11.0
40 bladder disease 11.0
41 neuroschistosomiasis 11.0
42 adenosquamous lung carcinoma 10.7 FGFR3 HRAS KRAS
43 sigmoid neoplasm 10.7 HRAS KRAS
44 lung squamous cell carcinoma 10.7 FGFR3 HRAS KRAS TUG1
45 apocrine adenoma 10.7 HRAS KRAS
46 periampullary adenoma 10.7 HRAS KRAS
47 esophageal cancer 10.7 GAS5 H19 HRAS KRAS MIR21 RB1
48 leukemia, acute myeloid 10.7 HRAS KRAS MIR21 MIR221 TUG1 UCA1
49 endometrial cancer 10.7 GAS5 H19 HRAS KRAS RB1 TUG1
50 paronychia 10.6 HRAS KRAS

Comorbidity relations with Bladder Cancer via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Cystitis Cystica Deficiency Anemia
Hydronephrosis Ischemic Heart Disease
Neutropenia Paralytic Ileus
Prostate Cancer Prostatic Hypertrophy
Radiation Cystitis Renal Pelvis Carcinoma
Ureter, Cancer of Urethral Benign Neoplasm
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Bladder Cancer:



Diseases related to Bladder Cancer
Sources

Symptoms & Phenotypes for Bladder Cancer

About this section

Human phenotypes related to Bladder Cancer:

33
# Description HPO Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder 33 HP:0006740

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
bladder cancer
transitional cell bladder carcinoma

Clinical features from OMIM:

109800
Sources

Drugs & Therapeutics for Bladder Cancer

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Valstar 19 VALRUBICIN Anthra Pharmaceuticals October 1998

Drugs for Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 537)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4,Phase 2 59467-70-8 4192
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
3
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
4
Alverine Approved, Investigational Phase 4 150-59-4 3678
5
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
7
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
8
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
9
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
10
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Benzocaine Approved, Investigational Phase 4,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
13
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
14
tannic acid Approved Phase 4,Phase 2,Not Applicable 1401-55-4
15
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
16
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18
Piroxicam Approved, Investigational Phase 4 36322-90-4 54676228 5280452
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
21
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
22
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
23
Parecoxib Approved Phase 4 198470-84-7
24
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
25
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
26
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
27
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
28
Alogliptin Approved Phase 4 850649-61-5 11450633
29
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
30
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
31
BCG vaccine Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
33
Fibrinolysin Investigational Phase 4 9004-09-5
34
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0
35 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Narcotics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 Analgesics, Opioid Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
40 Hypnotics and Sedatives Phase 4,Not Applicable
41 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
42 Omega 3 Fatty Acid Phase 4,Phase 3,Early Phase 1
43 Anticonvulsants Phase 4,Phase 2,Phase 3,Early Phase 1
44 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
45 Parasympatholytics Phase 4,Not Applicable
46 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
47 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1127)
# Name Status NCT ID Phase Drugs
1 The Assessment of POCD After TURBT Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
2 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
3 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
4 Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders Unknown status NCT03147599 Phase 4 Coloverin;Placebo
5 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Recruiting NCT02443844 Phase 4 Tamsulosin
6 Sequential Combination Therapy in Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
7 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4 hexaminolevulinate
8 Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer Completed NCT02214602 Phase 4 Epirubicin
9 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
10 Chemoradiotherapy for Recurrent T1G3 Bladder Cancer Not yet recruiting NCT03274284 Phase 4
11 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer Completed NCT03039543 Phase 4 Rocuronium;Sugammadex
12 "En Bloc" Resection of NMIBC: a Prospective， Single Centre，Randomized Study Not yet recruiting NCT03221062 Phase 4
13 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
14 Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach Recruiting NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
15 Investigation of Sugammadex in Outpatient Urological Procedures Active, not recruiting NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
16 Peri-operative Aspirin Continuation Versus Discontinuation Terminated NCT02350543 Phase 4 Aspirin
17 Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? Active, not recruiting NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
18 Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology Completed NCT02653261 Phase 4 Tranexamic Acid;Placebo
19 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Withdrawn NCT02734186 Phase 4 Praziquantel
20 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
21 Parecoxib for Treatment of Catheter Related Bladder Discomfort Completed NCT02729935 Phase 4 Parecoxib;Placebo
22 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Recruiting NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
23 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
24 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
25 Effects of a Neuroscience-based Technique on Post-traumatic Stress Disorder Symptoms, Inflammation, and Survival in Cancer Patients Announced of a Palliative Disease Progression and Their Partners Recruiting NCT03652298 Phase 4
26 The Practical Evidence of Antidiabetic Combination Therapy in Korea Completed NCT02231021 Phase 4 alogliptin;Pioglitazone;alogliptin + pioglitazone
27 A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer Unknown status NCT02951078 Phase 3
28 Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor Unknown status NCT01581723 Phase 3
29 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
30 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
31 Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer Unknown status NCT02074189 Phase 3 Gemcitabine, Cisplatin
32 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
33 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
34 Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection Unknown status NCT00816075 Phase 2, Phase 3 distilled water
35 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
36 The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer Unknown status NCT01489800 Phase 3
37 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
38 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
39 Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study Unknown status NCT01273987 Phase 2, Phase 3
40 The Bladder Instillation Comparison Study Unknown status NCT02695771 Phase 3 Mitomycin C;Gemcitabine
41 Tranexamic Acid During Cystectomy Trial (TACT) Unknown status NCT01869413 Phase 2, Phase 3 Tranexamic Acid;Placebo
42 Efficacy of Diclofenac BCG Irrigations Unknown status NCT01542567 Phase 3 Abitren;Placebo
43 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
44 Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) Recruiting NCT01675219 Phase 3 optimized MMC;single immediate chemotherapy instillation
45 Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer Recruiting NCT03664869 Phase 3 BCG instillation therapy;Sequential BCG and EMDA mitomycin C
46 Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer Recruiting NCT03298958 Phase 3 Rapamycin;Placebo Oral Tablet
47 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
48 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
49 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) Completed NCT00598806 Phase 3 Apaziquone;Placebo
50 Assessment of BladderLight SurvEILlance Not yet recruiting NCT03427034 Phase 2, Phase 3

Search NIH Clinical Center for Bladder Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer:
Neo-Urinary Conduit, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Cancer:
Neo-Urinary Conduit� PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder neoplasms

Sources

Genetic Tests for Bladder Cancer

About this section

Genetic tests related to Bladder Cancer:

# Genetic test Affiliating Genes
1 Bladder Cancer, Somatic 30 FGFR3 HRAS KRAS RB1
2 Bladder Carcinoma 30
Sources

Anatomical Context for Bladder Cancer

About this section

MalaCards organs/tissues related to Bladder Cancer:

42
Prostate, Testes, Lymph Node, Lung, T Cells, Kidney, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Cancer:

20
The Urinary Bladder
Sources

Publications for Bladder Cancer

About this section

Articles related to Bladder Cancer:

(show top 50) (show all 9251)
# Title Authors Year
1
Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis. ( 30387807 )
2019
2
Mycotic Aortic Aneurysm and Infected Aortic Graft After Intravesical Bacillus Calmette-Guérin Treatment for Bladder Cancer. ( 30213242 )
2019
3
Toward an Understanding of Patients' and Their Partners' Experiences of Bladder Cancer. ( 31033514 )
2019
4
BCG-induced discitis and osteomyelitis in a patient with a history of bladder cancer. ( 31033722 )
2019
5
Erratum to "Re: Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic". ( 31034017 )
2019
6
Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. ( 30837209 )
2019
7
Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. ( 30838338 )
2019
8
Robotic radical cystectomy with intracorporeal Studer pouch formation for bladder cancer: Experience in 98 cases. ( 30838878 )
2019
9
Immunotherapy in Bladder Cancer. ( 30839322 )
2019
10
Treatment delays for muscle-invasive bladder cancer. ( 30840318 )
2019
11
Delays in radical cystectomy for muscle-invasive bladder cancer. ( 30840335 )
2019
12
Green-laser assisted laparoscopic partial cystectomy for selective muscle-invasive bladder cancer: technique and initial outcome. ( 30843089 )
2019
13
Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years. ( 30844807 )
2019
14
PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. ( 30845932 )
2019
15
Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. ( 30846479 )
2019
16
Trimodality therapy for bladder cancer: modern management and future directions. ( 30855374 )
2019
17
Molecular subtyping of bladder cancer: current trends and future directions in 2019. ( 30855375 )
2019
18
Perioperative systemic therapy for bladder cancer. ( 30855376 )
2019
19
The impact of gender on oncologic outcomes of bladder cancer. ( 30855378 )
2019
20
Antitumor activity on human bladder cancer T-24 cells and composition analysis of the core of Camellia osmantha fruit. ( 30856009 )
2019
21
miR-182-5p affects human bladder cancer cell proliferation, migration and invasion through regulating Cofilin 1. ( 30858759 )
2019
22
circLPAR1 is a novel biomarker of prognosis for muscle-invasive bladder cancer with invasion and metastasis by miR-762. ( 30867795 )
2019
23
Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis. ( 30868054 )
2019
24
Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer. ( 30868237 )
2019
25
Back pain following instillations of BCG for superficial bladder cancer is not a reactive complication: review of 30 Mycobacterium bovis BCG vertebral osteomyelitis cases. ( 30868320 )
2019
26
SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake. ( 30868406 )
2019
27
APC promoter methylation is correlated with development and progression of bladder cancer, but not linked to overall survival: a meta-analysis. ( 30868894 )
2019
28
MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer. ( 30885775 )
2019
29
Bladder cancer with Indian ink. ( 30741659 )
2019
30
Treatment timing well tolerated in bladder cancer. ( 30742035 )
2019
31
Re: Human Epidermal Growth Factor Receptor 2 Expression is More Important than bacillus Calmette Guerin Treatment in Predicting the Outcome of T1G3 Bladder Cancer. ( 30759671 )
2019
32
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: . ( 30759672 )
2019
33
Bacillus Calmette-Guérin treatment of bladder cancer: a systematic review and commentary on recent publications. ( 30762672 )
2019
34
Upper urinary tract recurrence following bladder cancer therapy: a review of surveillance and management. ( 30762673 )
2019
35
Surveillance of non-muscle invasive bladder cancer using fluorescence in situ hybridization: Protocol for a systematic review and meta-analysis. ( 30762807 )
2019
36
Canadian Urological Association guideline: Muscle-invasive bladder cancer. ( 30763236 )
2019
37
Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.008. ( 30765160 )
2019
38
Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells. ( 30765842 )
2019
39
Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). ( 30765854 )
2019
40
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. ( 30765874 )
2019
41
Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer? ( 30785697 )
2019
42
Machine learning models for predicting post-cystectomy recurrence and survival in bladder cancer patients. ( 30785915 )
2019
43
LncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer. ( 30786017 )
2019
44
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer. ( 30786932 )
2019
45
Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC). ( 30805685 )
2019
46
Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. ( 30815670 )
2019
47
Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression. ( 30816487 )
2019
48
Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway. ( 30816494 )
2019
49
Chlorophyllin e6‑mediated photodynamic therapy inhibits proliferation and induces apoptosis in human bladder cancer cells. ( 30816498 )
2019
50
Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. ( 30819527 )
2019
Sources

Variations for Bladder Cancer

About this section

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer:

76
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Arg248Cys VAR_004148 rs121913482
2 FGFR3 p.Ser249Cys VAR_004149 rs121913483
3 FGFR3 p.Gly370Cys VAR_004151 rs121913479
4 FGFR3 p.Lys650Glu VAR_004160 rs78311289
5 FGFR3 p.Lys650Gln VAR_018390 rs78311289

ClinVar genetic disease variations for Bladder Cancer:

6 (show top 50) (show all 167)
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
3 KRAS NM_004985.4(KRAS): c.458A> T (p.Asp153Val) single nucleotide variant Pathogenic rs104894360 GRCh37 Chromosome 12, 25362838: 25362838
4 KRAS NM_004985.4(KRAS): c.458A> T (p.Asp153Val) single nucleotide variant Pathogenic rs104894360 GRCh38 Chromosome 12, 25209904: 25209904
5 HRAS NM_005343.2(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
6 HRAS NM_005343.2(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
7 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
8 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
9 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
10 RB1 RB1, IVS20, A-G, -2 single nucleotide variant Pathogenic
11 RB1 NM_000321.2(RB1): c.1981C> T (p.Arg661Trp) single nucleotide variant Pathogenic rs137853294 GRCh37 Chromosome 13, 49033844: 49033844
12 RB1 NM_000321.2(RB1): c.1981C> T (p.Arg661Trp) single nucleotide variant Pathogenic rs137853294 GRCh38 Chromosome 13, 48459708: 48459708
13 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 GRCh37 Chromosome 4, 1806119: 1806119
14 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 GRCh38 Chromosome 4, 1804392: 1804392
15 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
16 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
17 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs121913485 GRCh38 Chromosome 4, 1804372: 1804372
18 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 GRCh38 Chromosome 4, 1801837: 1801837
19 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic rs121913484 GRCh37 Chromosome 4, 1806092: 1806092
20 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic rs121913484 GRCh38 Chromosome 4, 1804365: 1804365
21 FGFR3 NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys) single nucleotide variant Pathogenic rs28933068 GRCh37 Chromosome 4, 1807371: 1807371
22 FGFR3 NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys) single nucleotide variant Pathogenic rs28933068 GRCh38 Chromosome 4, 1805644: 1805644
23 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
24 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh38 Chromosome 4, 1801841: 1801841
25 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 GRCh37 Chromosome 4, 1803571: 1803571
26 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 GRCh38 Chromosome 4, 1801844: 1801844
27 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
28 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 GRCh38 Chromosome 4, 1806162: 1806162
29 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic rs121913479 GRCh37 Chromosome 4, 1806089: 1806089
30 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic rs121913479 GRCh38 Chromosome 4, 1804362: 1804362
31 HRAS NM_005343.4(HRAS): c.520C> T (p.Pro174Ser) single nucleotide variant Benign rs397517144 GRCh37 Chromosome 11, 532686: 532686
32 HRAS NM_005343.4(HRAS): c.520C> T (p.Pro174Ser) single nucleotide variant Benign rs397517144 GRCh38 Chromosome 11, 532686: 532686
33 FGFR3 NM_000142.4(FGFR3): c.1949A> C (p.Lys650Thr) single nucleotide variant Pathogenic rs121913105 GRCh37 Chromosome 4, 1807890: 1807890
34 FGFR3 NM_000142.4(FGFR3): c.1949A> C (p.Lys650Thr) single nucleotide variant Pathogenic rs121913105 GRCh38 Chromosome 4, 1806163: 1806163
35 FGFR3 NM_001163213.1(FGFR3): c.2095G> T (p.Gly699Cys) single nucleotide variant Likely pathogenic rs121913480 GRCh37 Chromosome 4, 1808331: 1808331
36 FGFR3 NM_001163213.1(FGFR3): c.2095G> T (p.Gly699Cys) single nucleotide variant Likely pathogenic rs121913480 GRCh38 Chromosome 4, 1806604: 1806604
37 FGFR3 NM_000142.4(FGFR3): c.1993G> T (p.Ala665Ser) single nucleotide variant Uncertain significance rs764892330 GRCh37 Chromosome 4, 1808017: 1808017
38 FGFR3 NM_000142.4(FGFR3): c.1993G> T (p.Ala665Ser) single nucleotide variant Uncertain significance rs764892330 GRCh38 Chromosome 4, 1806290: 1806290
39 RB1 NM_000321.2(RB1): c.276T> G (p.Ile92Met) single nucleotide variant Uncertain significance rs1555282772 GRCh37 Chromosome 13, 48916746: 48916746
40 RB1 NM_000321.2(RB1): c.276T> G (p.Ile92Met) single nucleotide variant Uncertain significance rs1555282772 GRCh38 Chromosome 13, 48342610: 48342610
41 FGFR3 NM_000142.4(FGFR3): c.2153A> G (p.Asn718Ser) single nucleotide variant Uncertain significance rs139773438 GRCh37 Chromosome 4, 1808395: 1808395
42 FGFR3 NM_000142.4(FGFR3): c.2153A> G (p.Asn718Ser) single nucleotide variant Uncertain significance rs139773438 GRCh38 Chromosome 4, 1806668: 1806668
43 FGFR3 NM_000142.4(FGFR3): c.200G> A (p.Gly67Asp) single nucleotide variant Uncertain significance rs369232922 GRCh37 Chromosome 4, 1801071: 1801071
44 FGFR3 NM_000142.4(FGFR3): c.200G> A (p.Gly67Asp) single nucleotide variant Uncertain significance rs369232922 GRCh38 Chromosome 4, 1799344: 1799344
45 RB1 NM_000321.2(RB1): c.752G> A (p.Arg251Gln) single nucleotide variant Uncertain significance GRCh38 Chromosome 13, 48362848: 48362848
46 RB1 NM_000321.2(RB1): c.752G> A (p.Arg251Gln) single nucleotide variant Uncertain significance GRCh37 Chromosome 13, 48936984: 48936984
47 RB1 NM_000321.2(RB1): c.850A> G (p.Asn284Asp) single nucleotide variant Uncertain significance rs761609284 GRCh38 Chromosome 13, 48362946: 48362946
48 RB1 NM_000321.2(RB1): c.269G> T (p.Gly90Val) single nucleotide variant Uncertain significance rs554727080 GRCh37 Chromosome 13, 48916739: 48916739
49 RB1 NM_000321.2(RB1): c.269G> T (p.Gly90Val) single nucleotide variant Uncertain significance rs554727080 GRCh38 Chromosome 13, 48342603: 48342603
50 RB1 NM_000321.2(RB1): c.1215+1G> A single nucleotide variant Pathogenic rs587776783 GRCh38 Chromosome 13, 48373493: 48373493

Copy number variations for Bladder Cancer from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14770 1 110031964 110037890 Decreasing copy number GSTM1 Bladder cancer
2 16660 1 128900000 185800000 Gain Bladder cancer
3 18051 1 143699872 161705044 Gain Bladder cancer
4 36534 1 77068898 77170790 Loss Bladder cancer
5 51778 11 130615965 132678521 Loss Bladder cancer
6 53648 11 31517796 32050223 Loss Bladder cancer
7 58531 11 68323054 69297218 Gain Bladder cancer
8 67850 12 45466239 58591220 Gain Bladder cancer
9 75136 13 16000000 114142980 Copy number Bladder cancer
10 79497 13 72534137 72746128 Gain Bladder cancer
11 80757 13 97270228 100084626 Gain Bladder cancer
12 81341 14 101619009 102408085 Loss Bladder cancer
13 83177 14 19364851 19446107 Loss Bladder cancer
14 87829 14 77750645 79747731 Loss Bladder cancer
15 88246 14 88632756 89467875 Gain Bladder cancer
16 89915 15 19427350 19427409 Loss Bladder cancer
17 96847 15 95052889 95403459 Loss Bladder cancer
18 97491 16 10647794 11795463 Gain Bladder cancer
19 98997 16 22221235 32532138 Gain Bladder cancer
20 101674 16 45413780 45607724 Gain Bladder cancer
21 101856 16 46548299 69323131 Loss Bladder cancer
22 103047 16 5996067 6407032 Loss Bladder cancer
23 104499 16 69543004 70813070 Gain Bladder cancer
24 107647 17 1649595 1725887 Loss Bladder cancer
25 109050 17 24000000 38100000 Gain Bladder cancer
26 109225 17 24641926 27576519 Gain Bladder cancer
27 112300 17 38521264 78444637 Gain Bladder cancer
28 118108 17 7571719 7590863 Loss TP53 Bladder cancer
29 121742 18 467310 796252 Gain Bladder cancer
30 122814 18 61643142 67432063 Loss Bladder cancer
31 126424 19 18749534 19294814 Gain Bladder cancer
32 127148 19 278073 12616127 Gain Bladder cancer
33 127869 19 37856935 63485510 Gain Bladder cancer
34 135679 2 11956730 12796508 Gain Bladder cancer
35 135959 2 123437325 126399586 Loss Bladder cancer
36 138231 2 159948195 160120757 Loss Bladder cancer
37 141850 2 217249378 242464793 Loss Bladder cancer
38 146581 2 51236117 51635693 Loss Bladder cancer
39 147190 2 60966923 61033726 Loss Bladder cancer
40 147284 2 62081310 62298660 Loss Bladder cancer
41 148163 2 74469 50579433 Loss Bladder cancer
42 150320 2 9872881 10505097 Gain Bladder cancer
43 150974 20 157771 456225 Gain Bladder cancer
44 151125 20 17870221 18440898 Gain Bladder cancer
45 151502 20 22093371 26036562 Gain Bladder cancer
46 152003 20 28081598 47163674 Gain Bladder cancer
47 154726 20 48033501 54958791 Gain Bladder cancer
48 156571 20 61727753 62175139 Gain Bladder cancer
49 158507 21 33581851 34132794 Gain Bladder cancer
50 160744 22 16259597 16597551 Loss Bladder cancer
Sources

Expression for Bladder Cancer

About this section
Search GEO for disease gene expression data for Bladder Cancer.
Sources

Pathways for Bladder Cancer

About this section

Pathways related to Bladder Cancer according to KEGG:

38
# Name Kegg Source Accession
1 Bladder cancer hsa05219
2 MicroRNAs in cancer hsa05206

Pathways related to Bladder Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Glioma 38
Show member pathways
 12.52 FGFR3 HRAS KRAS RB1 TSC1
2
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.31 FGFR3 HRAS KRAS TSC1
3
Proteoglycans in cancer 38
12.1 HRAS KRAS MIR10B MIR21
4
Cellular senescence (KEGG) 38
11.94 HRAS KRAS RB1 TSC1
5
AKT Signaling Pathway 68
11.93 FGFR3 HRAS KRAS TSC1
6
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 11.84 FGFR3 HRAS KRAS RB1 TSC1
7
Glioblastoma Multiforme 65
11.67 HRAS KRAS RB1 TSC1
8
MicroRNAs in cancer 38
11.64 FGFR3 HRAS KRAS MIR10B MIR143 MIR21
9
Central carbon metabolism in cancer 38
11.5 FGFR3 HRAS KRAS
10
Aryl Hydrocarbon Receptor 1
11.31 HRAS KRAS RB1
11
Vemurafenib Pathway, Pharmacodynamics 62
11.21 FGFR3 HRAS KRAS
12
Bladder cancer 1 38
11.12 FGFR3 HRAS KRAS RB1
13
BDNF-TrkB Signaling 1
11.08 HRAS KRAS TSC1
14
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling 1
10.86 HRAS KRAS
15
MNAR-PELP1 and Estrogen Receptor Interaction 65
10.69 HRAS KRAS RB1
16
p38MAPK events 67
10.65 HRAS KRAS
Sources

GO Terms for Bladder Cancer

About this section

Cellular components related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 H19 MIR10B MIR127 MIR143 MIR21 MIR221

Biological processes related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.77 HRAS MIR21 MIR221 RB1 TSC1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 FGFR3 HRAS MIR21 MIR221
3 Ras protein signal transduction GO:0007265 9.58 HRAS KRAS RB1
4 positive regulation of protein kinase B signaling GO:0051897 9.56 FGFR3 MIR143 MIR21 MIR221
5 striated muscle cell differentiation GO:0051146 9.46 KRAS RB1
6 gene silencing by miRNA GO:0035195 9.43 H19 MIR10B MIR127 MIR143 MIR21 MIR221
7 negative regulation of GTPase activity GO:0034260 9.33 HRAS MIR21 TSC1
8 response to isolation stress GO:0035900 9.32 HRAS KRAS
9 positive regulation of vascular associated smooth muscle cell migration GO:1904754 8.8 MIR143 MIR21 MIR221

Molecular functions related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR10B MIR143 MIR21 MIR221
Sources

Sources for Bladder Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....